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Bone metabolic disruption that occurs in bone metastatic prostate cancer could lead to disturbances
of calcium metabolism. The prognostic role of either hypocalcemia or hypercalcemia was assessed
in a consecutive series of hormone-refractory bone metastatic prostate cancer patients. Serum
calcium was measured in 192 patients. The presence of hypocalcemia and hypercalcemia was
related with baseline biochemical and clinical characteristics and the role of these two calcium
disturbances in predicting prognosis and adverse skeletal-related events (SREs) was assessed. As
compared to normocalcemic patients, hypocalcemic patients (n¼ 51) had higher tumor load in bone
(P¼ 0.005), higher plasma chromogranin A (CgA, P¼ 0.01), serum alkaline phosphatase (P¼ 0.01),
urinary N-telopeptide (NTX, P¼ 0.002) and lower hemoglobin values (P¼ 0.01), while
hypercalcemic patients (n¼ 16) had higher plasma CgA (P¼ 0.001) and serum lactate
dehydrogenase values (P¼ 0.001), higher bone pain (P¼ 0.003) and a lower frequency of pure
osteoblastic lesions (P¼ 0.001). Hypercalcemia was significantly associated with poor prognosis:
hazard ratio (HR), 1.9 (95% confidence Interval (CI) 1.2–3.3) and higher risk to develop SREs HR, 2.5
(95% CI 1.2–5.2, P¼ 0.01), while hypocalcemia was not associated with poor prognosis. The
prognostic role of hypercalcemia was maintained in multivariate analysis after adjusting for
validated prognostic parameters: HR, 2.72 (95% CI 1.1–6.8, P¼ 0.03). These data suggest that serum
calcium levels should be taken into account in the clinical decision-making process of bone
metastatic prostate cancer patients. Patients with asymptomatic hypercalcemia could benefit of a
strict follow-up and an immediate bisphosphonate treatment. Further prospective clinical trials are
needed to confirm this finding.
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Introduction
Prostate cancer is the leading malignancy in the aging
male population1 and skeleton is the most frequent site
of metastatic disease.2 Metastatic cancer cells in bone
microenvironment release a number of cytokines and
growth factors that stimulate dysregulated bone resorp-
tion and bone formation resulting in lytic bone lesions,
blastic bone lesions or both.2 Metastatic bone lesions
from prostate cancer are typically osteoblastic.
The osteoblastic nature of bone lesions not with-
standing, osteolysis is a regular feature in bone meta-
static prostate cancer patients and may cause skeletal
morbidity.3 Increased osteoclast activity is not only
confined to metastatic sites, but may be also a general-
ized phenomenon related to secondary hyperparathyr-
oidism as a consequence of the so-called bone hunger
syndrome3,4 and due to osteoporosis induced by andro-
gen deprivation.3 Androgen deprivation is the mainstay
of therapy of advanced prostate cancer, this treatment
leads to serological and clinical improvement in more
than 90% of patients.5 Androgen deprivation therapy is
not curative and the majority of patients are destined to
progress to hormone-refractory disease. The prognosis of
hormone-refractory patients is dismal and the overall
survival is about 13–16 months on average.6,7 The
relatively long survival of these patients, however,
facilitates the onset of skeletal complications.3 Until the
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disease is responsive to androgen deprivation, adverse
skeletal events and metabolic disturbances are rare.8
However, they are more frequent when the tumor
become refractory to hormone manipulations.8
Calcium homeostasis is a tightly regulated process
involving the coordinated efforts of the skeleton,
kidney, parathyroid glands and intestine. Cancer cells
adversely affect mineral metabolism through a
broad spectrum of mechanisms.9 Neoplasms can cause
hypercalcemia through the production of endocrine
factors, notably parathyroid hormone-related peptides
(PTHrP). Hypercalcemia typically complicates the nat-
ural history of bone metastatic patients with predomi-
nantly lytic bone lesions, such as those with breast and
lung cancer.9 In patients with prostate cancer this
metabolic disturbance has been described exception-
ally.10–13 A number of factors could prevent the onset of
hypercalcemia in prostate cancer patients. The osteo-
blastic nature of bone lesions could lead to calcium
entrapment in bone.3,4 PTHrP may be produced by
prostate cancer14 but the prostate-specific antigen (PSA),
which is a kallikrein enzyme widely expressed by
prostate cancer cells, is able to cleave it.15
By contrast, the bone hunger syndrome induced
by prostate cancer bone metastases could predispose
patients to hypocalcemia and secondary hyperparathyr-
oidism in response to the increased calcium demand.3,4
Few papers, which are case reports or series of
symptomatic cases, reported data on hypercalcemia in
patients with prostate cancer.10–13 To our knowledge no
data are available on prevalence of supranormal
calcium levels in advanced prostate cancer population.
The prevalence of hypocalcemia in bone metastatic
prostate cancer patients has been reported in one
study showing that 43 of 131 patients (33%) had
calcium levels below the normal range.16 The
prognostic impact of either hypocalcemia or hypercalce-
mia has never been described, to the best of our
knowledge.
In this study, the frequency of hypocalcemia and
hypercalcemia was evaluated in a series of hormone-
refractory prostate cancer patients with metastatic bone
disease prospectively followed at the Prostate Cancer
Unit of the Azienda Ospedaliera San Luigi di Orbassano,
Italy. The primary aim of this study was to evaluate the
prognostic role of these metabolic disturbances, second-
ary aims were to evaluate the relationship of hypocalce-
mia and hypercalcemia with commonly recognized
prognostic parameters and to assess the role of these




Eligible patients were required to meet the following
inclusion criteria: histologically proven adenocarcinoma
of the prostate, metastatic bone disease as assessed by
bone scan followed by radiological confirmation of hot
spots, disease progression to androgen deprivation
therapy defined as a rise in PSA levels of 50% or more
over the nadir obtained during androgen deprivation
therapy on two consecutive measurements performed at
least 2 weeks apart, or a new lesion on bone scan and/or
an increase in the size of a measurable lesion on a
computed tomographic (CT) scan of the abdomen/pelvis
or chest. The time from diagnosis of hormone refractori-
ness to enrollment in the study should have been not
greater than 2 months.
Patients previously treated with luteinizing hormone-
releasing hormone analogues (LHRH-A) alone under-
went total androgen ablation by adding an antiandrogen
(flutamide or bicalutamide). They entered the study if
they showed further evidence of disease progression
after at least 4 weeks of combined therapy. Patients
previously treated with total androgen ablation were
required to undergo antiandrogen withdrawal. They
were required to be off all antiandrogen for at least 4
weeks, with further evidence of disease progression after
cessation of antiandrogen treatment. Serum testosterone
was routinely measured in all patients showing PSA
progression under LHRH-A since 1997.
From this date onward testosterone inhibition (defined
as serum levels o50 ng per 100 ml) was added to the
criteria of hormone refractoriness. Further inclusion
criteria consisted an Eastern Cooperative Oncology
performance status (PS) of 0–3 and normal renal and
hepatic function. Patients were excluded from the study
if they had severe uncontrolled comorbidity, second
malignancies, pretreatment with bisphosphonates, radio-
therapy or radionuclide therapy for palliation of bone
pain, and second-line antineoplastic treatment. At study
entry, all patients underwent physical examination,
including bone pain assessment, routine blood chemistry
studies, serum PSA, serum alkaline phosphatase (ALP),
plasma chromogranin A (CgA, the last 106 patients),
bone scan followed by radiological confirmation of
hot spots, chest X-ray and whole-abdomen CT, urinary
N-telopeptide (NTX, the last 103 patients). The whole
skeleton was arbitrarily divided into the following
areas: skull, cervical, dorsal, lumbar spineþ sacrum,
right leg, left leg, right arm, left arm, right ribs, left ribs,
sternum, right scapula and clavicula, left scapula
and clavicula, right pelvis and left pelvis. Disease extent
in bone was calculated as the sum of involved
areas. Baseline bone pain was evaluated using a
validated pain questionnaire, as previously reported.8
Items included PS, analgesic consumption and mobility,
as measured on a pain score of 0–19. All patients
subsequently received second-line treatments consisting
of endocrine therapy, chemotherapy, radiotherapy and
radionuclide therapy, as indicated in association with the
best palliative care.
Study end points
Survival duration was defined as the time between the
diagnosis of hormone-refractory disease and death.
Patients were censored if they were known to be alive
or were lost to follow-up. SREs were defined as vertebral
body collapse requiring spinal orthosis, spinal cord
compression, and vertebral and non-vertebral pathologic
fractures. The time to the onset of skeletal complications
was calculated as the time between the diagnosis of
hormone-refractory disease and the occurrence of the
first SRE or death, whichever event occurred first.
Patients were censored if they were alive and free of
SREs.
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Biochemical measurements
Early morning spot urine specimens were obtained to
measure creatinine and NTX; blood samples were drawn
to assess calcium, albumin, PSA, total ALP, lactate
dehydrogenase (LDH), hemoglobin and CgA. NTX was
measured using a commercial kit (Osteomark, Ortho-
Clinical Diagnostics, Rochester, NY, USA), plasma CgA
was measured using an enzyme-linked immunosorbent
assay kit (Dako, Glostrup, Denmark) serum PTH (intact
molecule) was measured by an immunoradiometric
assay (Nichols, San Juan Capistrano, CA, USA) that
does not cross-react with PTHrP.17,18 Measuring ranges,
minimum detectable concentrations, intra- and inter-
assay coefficients of variation were as follows: NTX
30–3000 nM, 20 nM, 4.4 and 6.9%; CgA 5–650 U l1, 2 U l1,
4.7 and 5.6%; PTH 2.5–2000 pg ml1, 2.1 pg ml1, 4.1
and 4.9%.
The remaining blood biochemical parameters, includ-
ing calcium, were measured using automated proce-
dures (Architect, Abbott, Rome, Italy). Calcium levels
were corrected for serum albumin; normal level was
defined as the range between 2.20 and 2.65 mmol l1,
values above and below this range were considered as
hypercalcemia and hypocalcemia, respectively.
Statistical analysis
Differences in proportion were determined using the
w2-test. Comparison of continuous variables was per-
formed using Mann–Whitney U-test for nonparametric
data. Survival curves were estimated using the Kaplan–
Meier method. A univariate Cox proportional hazards
model was used to assess whether hypocalcemia and
hypercalcemia were statistically significant predictors
of SREs and death. A multivariate Cox proportional
hazards model was used to identify independent
variables predictive of survival and onset of SREs. Serum
ALP, serum PSA and serum LDH had right-skewed
distributions and were modeled using log transforma-
tion. All reported P-values were two sided; P-values
o0.05 were considered statistically significant. Statistical
computation was performed using the SPSS for
Windows software package.
Results
From July 1990 to June 2003, 210 consecutive patients
with newly diagnosed hormone-refractory prostate
cancer met the inclusion criteria. Among them, 192 had
serum calcium assessed at baseline condition and
entered the present study. Patient characteristics are
depicted in Table 1. Most of patients had blastic bone
lesions, one-third had lytic/mixed bone lesions. Albu-
min-corrected serum calcium levels were above the
normal range in 16 patients (8.3%) and below the normal
range in 51 patients (26.6%). One-third of patients
received chemotherapy, and two-thirds steroids plus
supportive care. A total of 32 patients received a single-
dose pamidronate.19 Previous LHRH-A administration
was not interrupted in all cases.
After a median follow-up of 38 months, 167 patients
died (87.0%) and 84 patients (43.8%) experienced skeletal
complications: vertebral collapse in 41 (21.4%), fractures
in 24 (12.5%) and spinal cord compression in 19 (9.8%).
Three patients had symptomatic hypercalcemia, and one
patient had symptomatic hypocalcemia.
Relationship between calcium unbalances and clinical and
biochemical characteristics
Table 2 depicts the distribution of clinical and biochem-
ical variables according to calcium level status. As
expected, hypocalcemia was associated with greater
PTH levels and hypercalcemia with lower PTH values
than normocalcemia. Noteworthy, the great majority of
hypercalcemic patients had serum PTH at the inferior
limit of normality, two patients however showed
elevated PTH levels. These data suggest primary
hyperparathyroidism. As compared to normocalcemic
patients, patients with hypocalcemia had higher plasma
CgA, serum ALP, urinary NTX and lower hemoglobin
values. They also had a greater frequency of high tumor
load in bone. No difference in serum PSA, serum LDH,
Gleason score, bone pain and type of bone lesions was
observed between hypocalcemic and normocalcemic
patients.






Type of bone lesions (%)
Lytic/Mixed 55 (28.8)
Blastic 128 (67.0)
Bone scan+/Rx 8 (4.2)




Visceral metastases (%) 20 (10.4)
Pain scorea 5 (0–16)
Calcium (mmol l1)a 2.36 (1.91–4.20)
Hypocalcemia (%) 51 (26.6)
Normocalcemia (%) 125 (65.1)
Hypercalcemia (%) 16 (8.3)
PTH (pg ml1)a 49 (3.0–267.0)
Missing 41
Markers
CgA (U1)a 17.4 (3.0–394.0)
Missing 86
NTX (nM BCE/mmol CrU)a 101.5 (13.3–679.0)
Missing 84
ALP (U l1)a 162.0 (47.0–6000.0)
Missing 4
PSA (ng ml1)a 118 (0.1–9.000.0)
Missing 5
Hb (g per 100 ml)a 12.1 (7.3–15.6)
Missing 28
Abbreviations: ALP, alkaline phosphatase; BCE, bone collagen equivalents;
CgA, chromogranin A; Hb, hemoglobin; NTX, N-telopeptide; PSA, prostate-
specific antigen; PTH, parathyroid hormone.
aData are median and range.
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Hypercalcemic patients had higher plasma CgA and
serum LDH values, higher bone pain and a lower
frequency of pure blastic bone lesions than normocalce-
mic patients while there was no differences between the
two groups in terms of serum ALP, urinary NTX,
hemoglobin, serum PSA and Gleason score.
Predictive value of hypocalcemia and hypercalcemia on
patient outcome
Hypocalcemia and hypercalcemia conditions were also
analyzed to assess their predictive role with respect to
two outcome end points: death and onset of adverse
skeletal events.
Hypercalcemia was significantly associated with an
increased risk of either undergoing adverse skeletal
events or death, while hypocalcemia was not signifi-
cantly associated with the two outcome end points
(Figure 1). The prognostic role of hypercalcemia was also
maintained in multivariate analysis after adjusting for
validated prognostic parameters such as Gleason score,
serum PSA, presence of visceral metastases, serum ALP,
serum LDH and hemoglobin (Table 3).
Discussion
In cancer patients with bone metastases the focal
disruption of bone remodeling processes and the
systemic releases of calcium trophic hormones such as
PTHrP could lead to unbalances in calcium metabolism.9
The osteoblastic nature of secondary bone lesions and the
relative low frequency of PTHrP elevation due to PSA
cleavage predispose bone metastatic prostate cancer
patients to hypocalcemia, whereas hypercalcemia is
expected to be very rare. In our series of patients in
which albumin-corrected serum calcium levels were
systematically measured at the onset of hormone-
refractory disease, hypocalcemia was observed in about
27% and hypercalcemia in 8.3% of cases, confirming the
expectations. The frequency of hypocalcemic patients
observed in the present study was similar to that
observed by Murray et al. (32%)16 but the proportion of
hypercalcemic ones seems to be higher than the 0.5%
estimated in a comprehensive survey.10,12 While in the
paper by Murray et al. serum calcium levels were
measured in a consecutive series of cases as in the
present study, only symptomatic cases were included in
the previously mentioned survey and this is likely to
account for the discrepancies observed.
Hypocalcemic patients had higher PTH levels than
patients with normocalcemia in keeping with the
pathophysiology of the so-called bone hunger syn-
drome.3,4,8 Hypercalcemia in malignancy is mainly due
to the tumor production of PTHrP.9 We disclose the limit
of not having measured PTHrP but the low PTH levels
observed in our hypercalcemic patients are consistent
with PTHrP elevation since the IRMA assay we used for
PTH evaluation does not cross-react with PTHrP.9,17,18
Out of 151, two patients (1.3%), however, had elevated
levels of both serum calcium and PTH suggesting
primary hyperparathyroidism. Hyperparathyroidism
is frequent in the aged population,20 thus the association
Table 2 Variables distribution according to calcium level status
Hypocalcemia Normocalcemia Hypercalcemia
PTH(pg ml1)a 67.0 (10.0–267.0) 45.5 (10.0–199.0) 29.3 (3.0–115.0)
Pb 0.008 0.01
CgA(U l1)a 25.5 (5.2–302.0) 12.0 (3.0–394.0) 72.8 (3.0–174.0)
Pb 0.01 0.02
LDH(U l1)a 464.5 (166.0–2425.0) 406 (136.0–1940.0) 732.5 (366.0–3011.0)
Pb 0.15 0.001
PSA(ng ml1)a 100.0 (0.3–3393.0) 118 (0.1–9000.0) 200.0 (0.1–9000.0)
Pb 0.90 0.23
Hb(g per 100 ml)a 11.8 (7.7–15.6) 12.5 (7.3–15.6) 10.9 (9.3–14.8)
Pb 0.013 0.16
ALP(U l1)a 205.0 (47.0–6000.0) 137.0 (48.0–2486.0) 218.5 (47.0–2560.0)
Pb 0.015 0.14
NTXa
(nM BCE/mmol CrU) 191.0 (32.3–679.0) 96.2 (13.3–662.0) 145.3 (67.5–356.0)
Pb 0.002 0.08
PAIN scorea 5.5 (0–13) 5.0 (0–16) 8 (2–15)
Pb 0.30 0.003
Gleason score 47 30/51 (58.8%) 56/125 (44.8%) 12/18 (66.6%)
Pb 0.09 0.08
Visceral disease 6 /51 (11.8%) 14/124 (11.3%) 0/17 (0%)
Pb 0.92 0.21
High bonec
Tumor load 30/51 (58.8%) 44/123 (35.8%) 8/17 (47.1%)
Pb 0.005 0.37
Blastic bone lesions 37/51 (72.5%) 86/123 (69.9%) 5/17 (29.4%)
Pb 0.73 0.001
Abbreviations: ALP, alkaline phosphatase; BCE, bone collagen equivalents; CgA, chromogranin A; Hb, hemoglobin; LDH, lactate dehydrogenase; NTX,
N-telopeptide; PSA, prostate-specific antigen; PTH, parathyroid hormone.
aData are median and range.
bStatistical comparison of hypo or hypercalcemia versus normocalcemia.
c46 bone metastatic sites.
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with prostate cancer is not expected to be rare even if
precise estimates are not presently available. It has
been reported that PTHrP production in prostate cancer
patients correlates with the coexistence of neuroendo-
crine phenotype.21 In the 106 patients in which
plasma CgA was available, both hypercalcemic and
hypocalcemic patients had higher CgA values than
normocalcemic patients. Our data suggest that
neuroendocrine phenotype is associated with a greater
frequency of calcium unbalances but not necessarily with
hypercalcemia.
Metastatic bone lesions of prostate cancer are typically
osteoblastic, but bone lesions in patients with hypercal-
cemia were predominantly lytic/mixed. These data
suggest that prostate cancer biology of patients with
hypercalcemia may differ from that of normocalcemia or
hypocalcemia. In the present study, both hypercalcemia
and hypocalcemia correlated with some validated prog-
nostic parameters suggesting that both disturbances may
potentially identify patient subgroups with worse prog-
nosis than normocalcemic patients. However, outcome
analyses showed that hypercalcemia was correlated with
higher risk of adverse skeletal events and death but
hypocalcemia was not. Noteworthy, the prognostic role
of hypercalcemia was maintained after adjusting for
validated prognostic parameters suggesting that this
metabolic disturbance should be added in the prognostic
nomograms recently developed,6,7 a finding that needs
confirmation.
To conclude, calcium unbalance is a frequent condition
in hormone-refractory prostate cancer patients with
metastatic bone disease. Most patients had hypocalce-
mia, but the frequency of hypercalcemia was greater than
expected if asymptomatic cases are included. The
condition of hypercalcemia, whether symptomatic or
not, identifies a patient subset with predominantly lytic/
mixed bone lesions that are at higher risk of developing
SREs and death. This is a retrospective study with 192
patients recruited over a long time, during which some
changes occurred in clinical practice, this represents a
limitation and caution should be adopted in generalizing
the results. Our findings should be prospectively
evaluated in future clinical trials. These hindrances
notwithstanding physicians should to take into account
serum calcium levels in the clinical decision-making
process of prostate cancer patients with metastatic bone
disease. Patients with hypercalcemia could benefit of a
strict follow-up and may require an immediate bispho-
sphonate treatment.
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Figure 1 Time to first skeletal-related event (a) and overall
survival (b) of bone metastatic prostate cancer patients according
to calcium level status. Hazard ratio (HR, 95% confidence interval):
HR of hypocalcemic and hypercalcemic patients with respect to
patients with normocalcemia.
Table 3 Independent prognostic variables associated with overall
survival
HR (95% confidence interval) P
Log ALP 1.39 (1.10–1.77) 0.012
Log LDH 1.80 (1.20–2.71) 0.005
Hb 0.80 (0.72–0.90) 0.000
Gleason score 1.17 (0.99–1.39) 0.06
Serum Ca 2.72 (1.08–6.84) 0.034
Variables not in the model
Visceral metastases 1.22 (0.68–2.18) 0.52
Log PSA 1.04 (0.96–1.12) 0.36
Abbreviations: ALP, alkaline phosphatase; Hb, hemoglobin; LDH, lactate
dehydrogenase; PSA, prostate-specific antigen.
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